Get Premium to unlock powerful stock data

Dodge & Cox Global Stock Fund's 4th-Quarter Commentary

Discussion of markets and holdings

Author's Avatar
Jan 17, 2022
  • The Dodge & Cox Global Stock Fund’s total return was 3.3% for the fourth quarter of 2021, compared to 7.8% for the MSCI World Index.
Article's Main Image

The Dodge & Cox Global Stock Fund’s total return was 3.3% for the fourth quarter of 2021, compared to 7.8% for the MSCI World Index. For the twelve months ended December 31, 2021, the Fund generated a total return of 20.8%, compared to 21.8% for the MSCI World.

Investment Commentary

In the United States, the S&P 500 Index posted exceptionally strong results in 2021, up 29% on the back of a solid economy and unprecedented monetary and fiscal stimulus.

With strong consumer balance sheets and easy access to credit, demand continues to remain elevated. In contrast, COVID-19 variants, supply chain disruptions, and labor market frictions are affecting supply. Inflation is now at levels last seen in the 1980s, and the Federal Reserve has accelerated plans to raise interest rates in 2022.

Internationally, developed markets also posted solid results for the year (the MSCI EAFE Index appreciated 11%), as economic growth in most developed market countries rebounded to above pre-pandemic levels. However, the MSCI Emerging Markets Index declined 3%. China’s stock market dropped 22% amid ongoing regulatory interventions by the Chinese government and concerns about a slowdown in economic growth. Internet-related companies in particular were impacted, with the CSI China Internet Index down 49%.

During the first half of 2021, the global value indices appreciated and outperformed their growth counterparts.2 But in the second half of the year, value underperformed growth with the emergence of COVID-19 variants. Hence, while valuations remain above average for the market overall, wide valuation disparities remain between value and growth stocks. The MSCI World Value Index currently trades at 14.2 times forward earnings compared to a lofty 31.2 times for the MSCI World Growth Index.3 This market divergence is so rare it now rounds to the 100th percentile of historical experience. The discount for stocks that benefit from rising rates also continues to be extraordinarily wide. This valuation spread is particularly extraordinary given the incredibly low level of nominal and real interest rates, and would appear to suggest a greater likelihood of rates staying lower for longer than we believe is warranted.

These two wide valuation disparities provide attractive opportunities for active, value-oriented, bottom-up investment managers like Dodge & Cox. The Fund is overweight low-valuation stocks, which we believe are positioned to benefit from accelerating economic growth, and underweight growth stocks, which we believe are
more at risk due to their high valuations and high expectations. In 2021, we actively trimmed many of the Fund’s holdings as they outperformed the overall market, particularly in the more cyclical parts of the market that had benefited from a rebound in the economy. However, the Fund remains overweight Financials and Energy. In
Financials, the Fund’s holdings are inexpensive, well capitalized, and on track to return meaningful amounts of capital to shareholders in 2022. Although rising interest rates are not a core part of our investment thesis, higher rates would likely benefit earnings growth. In Energy, capital return potential is also poised to increase, as oil prices have risen and management teams have restrained capital spending.

Health Care was our largest add in the portfolio this year. As a result, the Fund’s Health Care position increased from 14.3% at the beginning of 2021 to 20.0% at year-end. We added to large pharmaceutical franchises such as GlaxoSmithKline (

GSK, Financial), Sanofi (SNY, Financial), and Novartis (NVS, Financial). These companies now represent three of the Fund’s five largest positions.4 We also started positions in the health care services company Fresenius Medical Care (FMS, Financial) (leading dialysis provider) and two biopharmaceutical companies: Regeneron Pharmaceuticals (REGN, Financial) and Incyte (INCY, Financial).

Regeneron is a biotech company focused on antibody treatments for ophthalmology, immunology, and cancer. Its antibody discovery platform has led to multiple commercial drugs, including two of the industry’s most valuable blockbusters, Eylea (ophthalmology) and Dupixent (immunology). The company has also made substantial investments in understanding the genetic basis of disease, as well as in new technologies like RNAi (with Alnylam) and CRISPR (with Intellia). The company is still led by its founding duo, CEO Len Schleifer and CSO George Yancopoulos, who are significant shareholders. Both are MD/PhDs and their strategy to focus on long-term value creation through innovation has been successful. We think Regeneron offers an opportunity to increase our exposure to innovation at an attractive price.

Going forward, we continue to be optimistic about the long-term outlook for the Fund. While timing is uncertain, we believe interest rates may increase further, which could benefit the Fund’s portfolio. Even if interest rates do not rise, the Fund could still benefit if the currently wide valuation discount for rising rate beneficiaries were to narrow. Finally, we believe the Fund is also well diversified and balanced across a range of investment themes. Over half of the Fund is invested in sectors and industries that benefit from innovation, in areas such as Media, Health Care, and Information Technology.

We believe patience, persistence, and a long-term investment horizon are essential to investment success. We encourage our shareholders to take a similar view. Thank you for your continued confidence in Dodge & Cox.

Fourth Quarter Performance Review

The Fund underperformed the MSCI World by 4.5 percentage points during the quarter.

Key Detractors from Relative Results

  • In Communication Services, the Fund’s average overweight position (15% versus 9%) and stock selection (down 5% compared to down 2% for the MSCI World sector) detracted. Charter Communications and Comcast were among the detractors.
  • The Fund’s relative results in the Consumer Discretionary sector (down 8% compared to up 8% for the MSCI World sector) also hurt. Alibaba was a main detractor.
  • Additional detractors included Axis Bank, Itau Unibanco, and Banco Santander.

Key Contributors to Relative Results

  • The Fund’s relative results in the Health Care sector (up 10% compared to up 8% for the MSCI World sector) contributed. GlaxoSmithKline was particularly strong.
  • Stock selection in the Energy sector (up 8% compared to up 4% for the MSCI World sector) also helped. Suncor Energy was a significant contributor.
  • Additional contributors included Jackson Financial and FedEx.

2021 Performance Review

The Fund underperformed the MSCI World by 1.1 percentage point in 2021.

Key Detractors from Relative Results

  • The Fund’s relative results in the Consumer Discretionary sector (down 23% compared to up 18% for the MSCI World sector) detracted. Alibaba underperformed.
  • Weaker relative results in the Health Care sector (up 15% compared to up 20% for the MSCI World sector) hurt results. Novartis was a key detractor.
  • In Communication Services, the Fund’s average overweight position (14% versus 9%) and stock selection (up 9% compared to up 15% for the MSCI World sector) also detracted. Comcast, Charter Communications, and Baidu were among the detractors.
  • The Fund’s average overweight position in emerging markets (14% versus not held in the MSCI World), the worst-performing region globally, contributed to underperformance. Key detractors included Alibaba and Baidu (previously mentioned), as well as Itau Unibanco.
  • Additional detractors included Credit Suisse and Mitsubishi Electric.

Key Contributors to Relative Results

  • Stock selection in the Energy sector (up 70% compared to up 40% for the MSCI World sector), combined with an average overweight position (7% versus 3%), contributed significantly. Outperformers included Ovintiv, Suncor Energy, and Occidental Petroleum.
  • The Fund’s stronger relative results in the Materials sector (up 45% compared to up 16% for the MSCI World sector) also helped. Glencore was a notable contributor.
  • In Financials, the Fund’s average overweight position (27% versus 14% for the MSCI World sector) also contributed meaningfully. Wells Fargo, Capital One Financial, and Charles Schwab were among the top contributors.
  • Additional contributors included Dell Technologies and Johnson Controls International.

1 The Fund’s total returns include the reinvestment of dividend and capital gain distributions, but have not been
adjusted for any income taxes payable by shareholders on these distributions or on Fund share redemptions.
Index returns include dividends but, unlike Fund returns, do not reflect fees or expenses. The MSCI World
Index is a broad-based, unmanaged equity market index aggregated from 23 Developed Market country
indices, including the United States. Results reflect dividends net of withholding taxes. MSCI makes no
express or implied warranties or representations and shall have no liability whatsoever with respect to any
MSCI data contained herein. The MSCI data may not be further redistributed or used as a basis for other
indices or any securities or financial products. This report is not approved, reviewed, or produced by MSCI. All
returns are stated in U.S. dollars, unless otherwise noted.

2 Generally, stocks that have lower valuations are considered “value” stocks, while those with higher valuations
are considered “growth” stocks.

3 Unless otherwise specified, all weightings and characteristics are as of December 31, 2021.

4 The use of specific examples does not imply that they are more or less attractive investments than the portfolio’s other holdings.

Returns represent past performance and do not guarantee future results. Investment return and share price will fluctuate with market conditions, and investors may have a gain or loss when shares are sold. Fund performance changes over time and currently may be significantly lower than stated above. Performance is updated and
published monthly. Visit the Fund’s website at or call 800-621-3979 for current month-end performance figures.

Also check out:


I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours. Click for the complete disclosure
0 / 5 (0 votes)
Author's Avatar

GuruFocus Screeners

Related Articles